StreetInsider.com News Articles

Iambic shares IAM1363 trial data at ESMO showing HER2 responses

Mon, 26 Oct 2026 08:01:43 -0400

Iambic Therapeutics (Nasdaq: IAM) presented updated clinical data for IAM1363, its HER2 tyrosine kinase inhibitor, at the European Society for Medical Oncology Congress in Madrid on October 23, 2026.

As of the August 31, 2026 data cutoff, 122 participants had received IAM1363 across the ongoing Phase 1/1b trial. Among participants with targetable HER2 alterations dosed at 960 mg or higher once daily, 36% achieved a partial response and 38% had stable disease by RECIST v1.1 criteria. Intracranial responses by modified RANO-BM showed a 41% partial response rate and 55% stable disease rate.

More than half of participants dosed at the 960 mg

Iambic shares IAM1363 trial data at ESMO showing HER2 responses

Mon, 26 Oct 2026 08:01:43 -0400

Iambic Therapeutics (Nasdaq: IAM) presented updated clinical data for IAM1363, its HER2 tyrosine kinase inhibitor, at the European Society for Medical Oncology Congress in Madrid on October 23, 2026.

More than half of participants dosed at the 960 mg

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers

Mon, 26 Oct 2026 08:00:00 -0400

IAM1363, now in a Phase 1/1b study, was designed using Iambic’s molecular superintelligence platform and brought to clinical development in approximately two years
Data presented at ESMO 2026 demonstrates IAM1363 was well tolerated with low rates of Grade 3 or higher treatment-related adverse events, serious adverse events, and dose modifications
More than half of participants dosed at 960 mg remain on study with some participants on treatment beyond one year
Intracranial responses were observed in participants with HER2-positive breast cancer who have previously received T-DXd and tucatinib

SAN DIEGO--(BUSINESS WIRE)-- Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers

Mon, 26 Oct 2026 08:00:00 -0400

IAM1363, now in a Phase 1/1b study, was designed using Iambic’s molecular superintelligence platform and brought to clinical development in approximately two years
Data presented at ESMO 2026 demonstrates IAM1363 was well tolerated with low rates of Grade 3 or higher treatment-related adverse events, serious adverse events, and dose modifications
More than half of participants dosed at 960 mg remain on study with some participants on treatment beyond one year
Intracranial responses were observed in participants with HER2-positive breast cancer who have previously received T-DXd and tucatinib

SAN DIEGO--(BUSINESS WIRE)-- Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life

Form 4 Iambic Therapeutics, For: Oct 16 Filed by: Petrocheilos George C

Mon, 19 Oct 2026 20:20:00 -0400

si-local-file:///var/storage/secattach/20261019/27205119.html

Form 4 Iambic Therapeutics, For: Oct 16 Filed by: Vogelstein R Jacob

Mon, 19 Oct 2026 19:53:00 -0400

si-local-file:///var/storage/secattach/20261019/27205074.html

Form 4 Iambic Therapeutics, For: Oct 16 Filed by: Secora Michael

Mon, 19 Oct 2026 19:51:00 -0400

si-local-file:///var/storage/secattach/20261019/27205072.html

Form 4 Iambic Therapeutics, For: Oct 16 Filed by: RASTETTER WILLIAM H

Mon, 19 Oct 2026 19:49:00 -0400

si-local-file:///var/storage/secattach/20261019/27205070.html

Form 4 Iambic Therapeutics, For: Oct 16 Filed by: Rachlin Evan Lockwood

Mon, 19 Oct 2026 19:47:00 -0400

si-local-file:///var/storage/secattach/20261019/27205067.html

Form 8-K Iambic Therapeutics, For: Oct 16

Fri, 16 Oct 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20261016/27198607.html

Form 4 Iambic Therapeutics, For: Oct 14 Filed by: EMSTER KURT VON

Fri, 16 Oct 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20261016/27198229.html

Form 4 Iambic Therapeutics, For: Oct 14 Filed by: Vogelstein R Jacob

Fri, 16 Oct 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20261016/27198217.html

Form 4 Iambic Therapeutics, For: Oct 14 Filed by: TAGLIAFERRI MARY

Fri, 16 Oct 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20261016/27198202.html

Form 4 Iambic Therapeutics, For: Oct 14 Filed by: Sharp Shalini

Fri, 16 Oct 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20261016/27198192.html

Form 4 Iambic Therapeutics, For: Oct 14 Filed by: RASTETTER WILLIAM H

Fri, 16 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261016/27198178.html

Form 4 Iambic Therapeutics, For: Oct 14 Filed by: Rachlin Evan Lockwood

Fri, 16 Oct 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20261016/27198167.html

Form 4 Iambic Therapeutics, For: Oct 14 Filed by: Secora Michael

Fri, 16 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261016/27198133.html

Form 4 Iambic Therapeutics, For: Oct 14 Filed by: Olson Peter A

Fri, 16 Oct 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20261016/27198080.html

Form 4 Iambic Therapeutics, For: Oct 14 Filed by: Josephson Neil

Fri, 16 Oct 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20261016/27198055.html

Form 4 Iambic Therapeutics, For: Oct 14 Filed by: Manby Frederick R

Fri, 16 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261016/27198019.html

Form 4 Iambic Therapeutics, For: Oct 14 Filed by: Miller Thomas F.

Fri, 16 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261016/27198005.html

Form 424B4 Iambic Therapeutics,

Thu, 15 Oct 2026 16:06:00 -0400

http://archive.fast-edgar.com/20261015/A42L9G2GZM2RKZZ2222O2ZYPDPT9ZZ22N282

Filed on: October 15, 2026

Form EFFECT Iambic Therapeutics,

Thu, 15 Oct 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20261015/27189141.html

Form S-8 Iambic Therapeutics,

Thu, 15 Oct 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20261015/27189003.html

Form 3 Iambic Therapeutics, For: Oct 14 Filed by: Petrocheilos George C

Wed, 14 Oct 2026 20:41:00 -0400

si-local-file:///var/storage/secattach/20261014/27188224.html